AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32167393 — intervention group
Group type: COMPARATOR
Intervention: Placebo + cytarabine
Number of subjects: 0
Study 33340674 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3−‐rich beetroot powder (5 g/d contains 250 mg NO3−)
Number of subjects: 74
Study 33340674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 32365613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-system Physical Exercise (MPE) group, n = 36
Number of subjects: 72
Study 32365613 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 36
Number of subjects: 72
Study 35064330 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D head‐mounted (HMD) virtual reality (VR)
Number of subjects: 13
Study 35064330 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D screen applications
Number of subjects: 13
Study 35064330 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 3D HMD VR and 2D screen applications
Number of subjects: 13
Study 34810362 — intervention group
Group type: EXPERIMENTAL
Intervention: Photofunctionalization (PF group)
Number of subjects: 90
Study 34810362 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP group)
Number of subjects: 90
Study 34810362 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard tapered root form implant without pretreatment)
Number of subjects: 90
Study 32353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg orally every 12 hours on days 1-21 of a 21-day cycle), trastuzumab (8 mg/kg on cycle 1 day 1, then 6 mg/kg on day 1 of each subsequent cycle), and fulvestrant (500 mg on days 1, 15, and 29, then once every 4 weeks thereafter)
Number of subjects: 237
Study 32353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib (150 mg orally every 12 hours on days 1-21 of a 21-day cycle) and trastuzumab (8 mg/kg on cycle 1 day 1, then 6 mg/kg on day 1 of each subsequent cycle)
Number of subjects: 237
Study 32353342 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy plus trastuzumab
Number of subjects: 237
Study 32353342 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib, fulvestrant, and trastuzumab
Number of subjects: 237
Study 32250132 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition Training Program (SCTP), 12 sessions
Number of subjects: 299
Study 32250132 — intervention group
Group type: COMPARATOR
Intervention: Neurocognitive training
Number of subjects: 299
Study 32997761 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Debridement (FD)
Number of subjects: 300
Study 32997761 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Debridement (PD)
Number of subjects: 300
Study 32997761 — intervention group
Group type: COMPARATOR
Intervention: Control group (debridement simulation)
Number of subjects: 300
Study 33781616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization using genetic variants as instrumental variables
Number of subjects: 0
Study 32661681 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin-enriched orange juice (EOJ)
Number of subjects: 159
Study 32661681 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice (OJ)
Number of subjects: 159
Study 32661681 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 159
Study 35729605 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-activated delivery of cognitive behavioral therapy for insomnia (CBT-I) components using a smart speaker device for 6 weeks.
Number of subjects: 100
Study 35729605 — intervention group
Group type: COMPARATOR
Intervention: Sleep education control using a website with basic information about CBT-I, sleep, and breast cancer survivorship.
Number of subjects: 100
Study 32069319 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body muscle strength at 16th week
Number of subjects: 159
Study 32069319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal flexibility at 16th week
Number of subjects: 159
Study 32069319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cardiorespiratory fitness (CRF) at 16th week
Number of subjects: 159
Study 32069319 — intervention group
Group type: COMPARATOR
Intervention: Overall physical fitness at 16th and 34th weeks
Number of subjects: 159
Study 35392766 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaling 800 µg salbutamol
Number of subjects: 27
Study 35392766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 34167597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Quality Index-International (DQI-I)
Number of subjects: 726
Study 34167597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Phytochemical Index (DPI)
Number of subjects: 726
Study 34167597 — intervention group
Group type: EXPERIMENTAL
Intervention: T-allele carriers with highest level of PGF2α
Number of subjects: 726
Study 34167597 — intervention group
Group type: EXPERIMENTAL
Intervention: CCs in the second tertile of DPI
Number of subjects: 726
Study 32017817 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation program (Gr. 2)
Number of subjects: 0
Study 32017817 — intervention group
Group type: COMPARATOR
Intervention: No structured rehabilitation (Gr. 1)
Number of subjects: 0
Study 35578268 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 µg/day)
Number of subjects: 0
Study 32493276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (intravenous bolus 1.5 mg/kg followed by an infusion of 2 mg/kg/h)
Number of subjects: 64
Study 32493276 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (equal volume to lidocaine)
Number of subjects: 64
Study 32493276 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 64
Study 32493276 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 64
Study 34255321 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic stimulation
Number of subjects: 10
Study 34255321 — intervention group
Group type: COMPARATOR
Intervention: BurstDR stimulation
Number of subjects: 10
Study 34255321 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 33098953 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan treatment
Number of subjects: 66
Study 33098953 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 66
Study 33098953 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline aortic root measurement
Number of subjects: 66
Study 33098953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic root growth after 2 years
Number of subjects: 66
Study 36428062 — intervention group
Group type: EXPERIMENTAL
Intervention: Online HOPE intervention
Number of subjects: 0
Study 36428062 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36428062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 34452669 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise
Number of subjects: 255
Study 34452669 — intervention group
Group type: EXPERIMENTAL
Intervention: Body functionality writing exercise
Number of subjects: 255
Study 34452669 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session online intervention
Number of subjects: 255
Study 34452669 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 255
Study 33044421 — intervention group
Group type: EXPERIMENTAL
Intervention: PalliActive Caregivers intervention
Number of subjects: 80
Study 33044421 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 33044421 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 80
Study 34285282 — intervention group
Group type: EXPERIMENTAL
Intervention: G-PUR 2.0 g
Number of subjects: 42
Study 34285282 — intervention group
Group type: EXPERIMENTAL
Intervention: G-PUR 2 * 2.0 g
Number of subjects: 42
Study 34285282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 33052122 — intervention group
Group type: EXPERIMENTAL
Intervention: ImTeCHO intervention
Number of subjects: 5754
Study 33052122 — intervention group
Group type: COMPARATOR
Intervention: Routine maternal, neonatal, and child health care programs
Number of subjects: 5754
Study 35098782 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial flow oxygenator
Number of subjects: 52
Study 35098782 — intervention group
Group type: COMPARATOR
Intervention: Axial flow oxygenator
Number of subjects: 52
Study 35098782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 32732354 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 50
Study 36098028 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidomain intervention (16 2-hour sessions per year including physical exercise, cognitive training, nutrition and disease education, plus individualized treatment by specialists)
Number of subjects: 398
Study 36098028 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated multidomain intervention
Number of subjects: 398
Study 36098028 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 398
Study 34057659 — intervention group
Group type: EXPERIMENTAL
Intervention: U=U messaging
Number of subjects: 1048
Study 34057659 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 1048
Study 33378495 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g of intrusive force
Number of subjects: 22
Study 33378495 — intervention group
Group type: COMPARATOR
Intervention: 200 g of intrusive force
Number of subjects: 22
Study 35841908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg followed by 500 mg every 6 months)
Number of subjects: 200
Study 35841908 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (240 mg twice daily)
Number of subjects: 200
Study 35841908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 200
Study 35841908 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate
Number of subjects: 200
Study 33910364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exo group (mechanized device - Armeo Spring)
Number of subjects: 215
Study 33910364 — intervention group
Group type: COMPARATOR
Intervention: Control group (stretching plus basic active exercises)
Number of subjects: 215
Study 32339745 — intervention group
Group type: EXPERIMENTAL
Intervention: O-arm
Number of subjects: 58
Study 32339745 — intervention group
Group type: COMPARATOR
Intervention: C-arm
Number of subjects: 58
Study 32339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 32339745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral TAS fixation
Number of subjects: 58
Study 36153457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pricking and cupping therapy + Chinese herbal wet compress + basic treatment
Number of subjects: 232
Study 36153457 — intervention group
Group type: COMPARATOR
Intervention: Pricking and cupping + basic treatment
Number of subjects: 232
Study 36153457 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal wet compress + basic treatment
Number of subjects: 232
Study 36153457 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 232
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Unintentional injuries prevalence
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Age increase from 2 to 5 years
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of working mothers
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Families with more than 3 children
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Households without a separate kitchen
Number of subjects: 650
Study 32893826 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with inadequate lighting
Number of subjects: 650
Study 33527413 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraAC (Ultraconservative access cavity preparation)
Number of subjects: 60
Study 33527413 — intervention group
Group type: COMPARATOR
Intervention: TradAC (Traditional access cavity preparation)
Number of subjects: 60
Study 33527413 — intervention group
Group type: COMPARATOR
Intervention: TradAC
Number of subjects: 60
Study 33527413 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraAC
Number of subjects: 60
Study 33099541 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 0
Study 33099541 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood body size (plumper than average at age 10)
Number of subjects: 0
Study 33099541 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanning habits (very tanned or moderately tanned)
Number of subjects: 0
Study 33099541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable MR analysis for age at menarche
Number of subjects: 0
Study 33099541 — intervention group
Group type: EXPERIMENTAL
Intervention: MR analysis for ease of tanning
Number of subjects: 0
Study 33099541 — intervention group
Group type: COMPARATOR
Intervention: MR‐EWAS approach
Number of subjects: 0
Study 35853695 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint using joint frailty modeling in response-adaptive randomization.
Number of subjects: 0
Study 35853695 — intervention group
Group type: COMPARATOR
Intervention: Balanced randomized design.
Number of subjects: 0
Study 33626877 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose of protamine (1 mg per mg heparin used)
Number of subjects: 90
Study 33626877 — intervention group
Group type: COMPARATOR
Intervention: Lower dose of protamine (0.8 mg per mg heparin used)
Number of subjects: 90
Study 32537643 — intervention group
Group type: EXPERIMENTAL
Intervention: Modestly lower carbohydrate diet (MLC, ∼135 g/d carbohydrate)
Number of subjects: 46
Study 32537643 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC, ∼200 g/d carbohydrate)
Number of subjects: 46
Study 32537643 — intervention group
Group type: EXPERIMENTAL
Intervention: Modestly lower carbohydrate diet (MLC)
Number of subjects: 46
Study 32537643 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 46
Study 34702395 — intervention group
Group type: EXPERIMENTAL
Intervention: Total annulus excision tympanoplasty (group B)
Number of subjects: 56
Study 34702395 — intervention group
Group type: COMPARATOR
Intervention: Conventional tympanoplasty (group A)
Number of subjects: 56
Study 32897368 — intervention group
Group type: EXPERIMENTAL
Intervention: Suptavumab (1 dose)
Number of subjects: 1154
Study 32897368 — intervention group
Group type: EXPERIMENTAL
Intervention: Suptavumab (2 doses)
Number of subjects: 1154
Study 32897368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1154
Study 35717999 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 32856379 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily life activities simulation
Number of subjects: 119
Study 32856379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study 33481114 — intervention group
Group type: EXPERIMENTAL
Intervention: Joy Luck Academy program (weekly education and peer-mentor support sessions)
Number of subjects: 129
Study 35909334 — intervention group
Group type: COMPARATOR
Intervention: Iron–folic acid (IFA) capsule (control)
Number of subjects: 1391
Study 35909334 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient (MMN) capsule of 18 micronutrients (second control)
Number of subjects: 1391
Study 35909334 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐quantity lipid‐based nutrient supplements (SQ‐LNS)
Number of subjects: 1391
Study 34216630 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress disorder in parents
Number of subjects: 153
Study 34216630 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptom severity
Number of subjects: 153
Study 34216630 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-traumatic stress symptom clusters (avoidance, arousal, re-experiencing)
Number of subjects: 153
Study 34158672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucolytic solution (100 mL water + 400 mg N-acetylcysteine + 20 mg simethicone)
Number of subjects: 134
Study 34158672 — intervention group
Group type: COMPARATOR
Intervention: Control group (without the solution)
Number of subjects: 134
Study 34158672 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 mL pure water)
Number of subjects: 134
Study 33908285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic-hyperinsulinemia
Number of subjects: 0
Study 34491648 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (horizontal penetration needling combined with rizatriptan monobenzoate tablets)
Number of subjects: 99
Study 34491648 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (horizontal penetration needling)
Number of subjects: 99
Study 34491648 — intervention group
Group type: COMPARATOR
Intervention: Western medication (rizatriptan monobenzoate tablets 10 mg)
Number of subjects: 99
Study 32293363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 120
Study 32293363 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronobiological Therapy (CT)
Number of subjects: 120
Study 32293363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I) + Chronobiological Therapy (CT)
Number of subjects: 120
Study 32293363 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 34853784 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT)
Number of subjects: 64
Study 32450273 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body tilting postural training (WTPT) using a Spine Balance 3D
Number of subjects: 30
Study 32450273 — intervention group
Group type: COMPARATOR
Intervention: General postural training (GPT)
Number of subjects: 30
Study 32450273 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body tilting postural training (WTPT)
Number of subjects: 30
Study 32247517 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental instrumental feeding
Number of subjects: 534
Study 32247517 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental emotional feeding
Number of subjects: 534
Study 35722977 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla frutescens seed oil (PO) 1.47 mL daily (0.88 g ALA)
Number of subjects: 0
Study 35722977 — intervention group
Group type: COMPARATOR
Intervention: Perilla frutescens seed oil (PO) 1.47 mL daily (0.88 g ALA) and Anredera cordifolia leaf powder 1.12 g daily (1.46 mg vitexin and 1.12 mg adenosine)
Number of subjects: 0
Study 32019524 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Leadership course
Number of subjects: 52
Study 35983524 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized health management mode based on the Internet mode
Number of subjects: 60
Study 35362717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C acid stimulation
Number of subjects: 120
Study 35362717 — intervention group
Group type: COMPARATOR
Intervention: Routine swallowing training (Control)
Number of subjects: 120
Study 35331251 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick Blood Smear (TBS)
Number of subjects: 24
Study 35331251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasensitive Rapid Diagnostic Test (uRDT)
Number of subjects: 24
Study 35331251 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rapid Diagnostic Test (cRDT)
Number of subjects: 24
Study 35331251 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative PCR (qPCR)
Number of subjects: 24
Study 32653012 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-only group receiving dairy products to increase protein intake to 1.5 g/kg/day
Number of subjects: 150
Study 32653012 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + exercise group receiving protein intervention and power training two times a week
Number of subjects: 150
Study 32653012 — intervention group
Group type: COMPARATOR
Intervention: Recommendation group continuing as in phase 1
Number of subjects: 150
Study 32653012 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-only group
Number of subjects: 150
Study 32653012 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein + exercise group
Number of subjects: 150
Study 32653012 — intervention group
Group type: COMPARATOR
Intervention: Recommendation group
Number of subjects: 150
Study 35714276 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-W
Number of subjects: 2400
Study 35714276 — intervention group
Group type: COMPARATOR
Intervention: TIV1
Number of subjects: 2400
Study 35714276 — intervention group
Group type: COMPARATOR
Intervention: TIV2
Number of subjects: 2400
Study 35239971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon (0.6 mg)
Number of subjects: 170
Study 32149879 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE) for 30 minutes at 50-55% of heart rate reserve (HRR)
Number of subjects: 19
Study 32149879 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Exercise (HIIE) consisting of 10 × 1 minute at 80-85% of HRR and 2 minutes at 40-45% of HRR
Number of subjects: 19
Study 32149879 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 19
Study 35152575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of mecobalamin
Number of subjects: 98
Study 35152575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitalstim electrical stimulation
Number of subjects: 98
Study 35152575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acupoint injection and Vitalstim electrical stimulation
Number of subjects: 98
Study 36202733 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 12 weeks
Number of subjects: 43
Study 36202733 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43
Study 34392865 — intervention group
Group type: EXPERIMENTAL
Intervention: Slide presentation (Group 1; SP‐G)
Number of subjects: 60
Study 34392865 — intervention group
Group type: EXPERIMENTAL
Intervention: Video clip (Group 2; V‐G)
Number of subjects: 60